Viridian Therapeutics (NASDAQ:VRDN) Given New $32.00 Price Target at Needham & Company LLC

Viridian Therapeutics (NASDAQ:VRDN) had its target price lowered by Needham & Company LLC from $42.00 to $32.00 in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

VRDN has been the subject of a number of other reports. Wells Fargo & Company upped their price target on Viridian Therapeutics from $26.00 to $29.00 and gave the company an “equal weight” rating in a report on Tuesday, February 3rd. UBS Group assumed coverage on shares of Viridian Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price objective for the company. Evercore restated an “outperform” rating and issued a $44.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Wednesday, January 21st. Finally, William Blair initiated coverage on Viridian Therapeutics in a research report on Wednesday, December 3rd. They set an “outperform” rating on the stock. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.50.

Viridian Therapeutics Stock Down 32.3%

Shares of NASDAQ VRDN opened at $18.53 on Monday. The business has a 50-day moving average of $29.42 and a two-hundred day moving average of $27.88. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of -5.63 and a beta of 1.00. Viridian Therapeutics has a 1 year low of $9.90 and a 1 year high of $34.29. The company has a debt-to-equity ratio of 0.08, a current ratio of 12.65 and a quick ratio of 12.65.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%. The business had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $15.75 million. On average, analysts forecast that Viridian Therapeutics will post -4.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 2,272 shares of the business’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $31.16, for a total transaction of $70,795.52. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.65% of the company’s stock.

Hedge Funds Weigh In On Viridian Therapeutics

A number of large investors have recently made changes to their positions in the stock. ANTIPODES PARTNERS Ltd purchased a new stake in Viridian Therapeutics during the fourth quarter worth about $36,000. Aster Capital Management DIFC Ltd purchased a new position in Viridian Therapeutics in the third quarter valued at about $35,000. Farther Finance Advisors LLC increased its holdings in Viridian Therapeutics by 332.1% in the third quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock valued at $42,000 after buying an additional 1,491 shares in the last quarter. Bessemer Group Inc. lifted its position in shares of Viridian Therapeutics by 947.7% during the 3rd quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock valued at $45,000 after acquiring an additional 1,886 shares during the period. Finally, Larson Financial Group LLC acquired a new stake in shares of Viridian Therapeutics during the 3rd quarter valued at approximately $52,000.

Key Stories Impacting Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: REVEAL‑1 met its primary endpoint: elegrobart showed higher proptosis responder rates versus placebo at week 24, supporting efficacy of the subcutaneous candidate. Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
• Neutral Sentiment: Analyst action: Needham cut its price target from $42 to $32 but maintained a Buy rating, signaling some sell‑side confidence in longer‑term commercial potential despite near‑term uncertainty. Benzinga note on Needham price target
• Negative Sentiment: Heavy sell‑off and volume spike — shares plunged over 30% on the day of the topline release as investors rushed to reprice VRDN amid limited detail beyond the primary endpoint. Viridian Therapeutics shares fall over 30% after trial data disappoints
• Negative Sentiment: Market disappointment despite “success” — reports note the topline numbers (proptosis responder rates of ~54% Q4W and ~63% Q8W vs 18% placebo) were not enough to satisfy expectations; investors want full primary and key secondary endpoint details, safety, and subgroup data before re‑rating the stock. Why Is Viridian Therapeutics Stock Falling Monday?
• Negative Sentiment: Coverage highlighting the paradox — multiple outlets emphasize that the stock tumbled “despite trial success,” reflecting investor concern about incomplete disclosure and potential questions around dosing consistency, secondary endpoints or safety that could affect regulatory and commercial outlook. Viridian Therapeutics stock tumbles despite trial success

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.